Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.65 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146280 | 0.85 | BRAF (0.74) | BRAFEIF2AK2 | |
| SCHEMBL16145749 | 0.82 | BRAF (0.72) | BRAFEIF2AK2TNNI3K | |
| SCHEMBL16146118 | 0.82 | BRAF (0.72) | BRAFEIF2AK2TNNI3K | |
| SCHEMBL5355413 | 0.82 | BRAF (0.73) | BRAFEIF2AK2TNNI3K | |
| SCHEMBL795950 | 0.80 | MKNK1 (0.68) | BRAFTNNI3K | |
| SCHEMBL12969352 | 0.78 | ROCK1 (0.69) | BRAFEIF2AK2TNNI3K | |
| Hydrochloric Acid SCHEMBL12813276 | 0.77 | ROCK1 (0.67) | BRAFEIF2AK2TNNI3K | |
| SCHEMBL16146677 | 0.75 | BRAF (1.00) | BRAFTNNI3K | |
| SCHEMBL30523356 | 0.75 | BRAF (1.00) | BRAFTNNI3K | |
| SCHEMBL164700 | 0.74 | XDH (0.65) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2616474-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | Centre National De La Recherche Scientifique (FR) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034719-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | PNP, TYMP, EIF2AK2 | BRAF 3330/4885EIF2AK2 3/4885TNNI3K 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.